How Open Science Is Keeping Allergan's R&D Pipeline Strong
Allergan's chief R&D officer David Nicholson discusses the company's "open science model" to innovation and innovating, and highlights some of the promising device-based technologies it recently acquired and is developing.
You may also be interested in...
Allergan Pays $2bn-Plus For Zeltiq, Expanding Aesthetics Business
Zeltiq's CoolSculpting body-contouring system will be the third "pillar" in Allergan's aesthetics business, along with its existing facial aesthetics and plastic and regenerative surgery lines, the company says.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.